Targeting HMGB1 in the treatment of sepsis

H Wang, MF Ward, AE Sama - Expert opinion on therapeutic targets, 2014 - Taylor & Francis
Introduction: Sepsis refers to the host's deleterious and non-resolving systemic inflammatory
response to microbial infections and represents the leading cause of death in the intensive …

Therapeutic potential of HMGB1-targeting agents in sepsis

H Wang, S Zhu, R Zhou, W Li… - Expert reviews in molecular …, 2008 - cambridge.org
Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial
infection. The inflammatory response is partly mediated by innate immune cells (such as …

HMGB1 as a therapeutic target for sepsis: it's all in the timing!

LF Gentile, LL Moldawer - Expert opinion on therapeutic targets, 2014 - Taylor & Francis
Morbidity and mortality from severe sepsis remain high, despite decades of research and
improvements in intensive care unit (ICU) care. There have been over 100 failed clinical …

Endogenous regulation and pharmacological modulation of sepsis-induced HMGB1 release and action: An updated review

CS Zhu, W Wang, X Qiang, W Chen, X Lan, J Li… - Cells, 2021 - mdpi.com
Sepsis remains a common cause of death in intensive care units, accounting for
approximately 20% of total deaths worldwide. Its pathogenesis is partly attributable to …

HMGB1 as a potential therapeutic target

H Wang, W Li, R Goldstein, KJ Tracey… - Sepsis: New Insights …, 2006 - Wiley Online Library
Despite recent advances in antibiotic therapy and intensive care, sepsis remains the most
common cause of death in the intensive care units, claiming approximately 225 000 victims …

Novel HMGB1-inhibiting therapeutic agents for experimental sepsis

H Wang, MF Ward, AE Sama - Shock, 2009 - journals.lww.com
Sepsis refers to a systemic inflammatory response syndrome resulting from a microbial
infection. The inflammatory response is partly mediated by innate immune cells (such as …

Therapeutic targeting of HMGB1 during experimental sepsis modulates the inflammatory cytokine profile to one associated with improved clinical outcomes

NE Stevens, MJ Chapman, CK Fraser, TR Kuchel… - Scientific reports, 2017 - nature.com
Sepsis remains a significant health burden and a major clinical need exists for therapeutics
to dampen the excessive and uncontrolled immune activation. Nuclear protein high mobility …

High mobility group box 1 protein as a potential drug target for infection-and injury-elicited inflammation

S Zhu, W Li, MF Ward, AE Sama… - Inflammation & Allergy …, 2010 - ingentaconnect.com
In response to infection or injury, a ubiquitous nucleosomal protein, HMGB1 is secreted
actively by innate immune cells, and/or released passively by injured/damaged cells …

Bench to Bedside: HMGB1—A Novel Proinflammatory Cytokine and Potential Therapeutic Target for Septic Patients in the Emergency Department

AE Sama, J D'Amore, MF Ward… - Academic Emergency …, 2004 - Wiley Online Library
Overwhelming gram‐negative bacterial infection and life‐threatening systemic inflammation
are widespread problems in critically ill emergency department patients. Currently, the …

Targeting HMGB1 for the treatment of sepsis and sepsis-induced organ injury

C Deng, L Zhao, Z Yang, J Shang, C Wang… - Acta Pharmacologica …, 2022 - nature.com
High mobility group box 1 (HMGB1) is a ubiquitous nuclear protein that is present in almost
all cells and regulates the activity of innate immune responses in both intracellular and …